1) The document discusses atrial fibrillation (AF), its increasing prevalence, and its association with increased risk of stroke.
2) It reviews stroke risk assessment tools like CHADS2 and CHA2DS2-VASc scores and guidelines for stroke prevention in AF patients using anticoagulation or the newer oral anticoagulants (NOACs).
3) It also discusses left atrial appendage closure with the Watchman device as an alternative for stroke prevention in patients who cannot tolerate long-term anticoagulation. The Watchman trials demonstrated the device's safety and efficacy in reducing stroke risk comparable to warfarin.
2. The estimated US prevalence of atrial fibrillation (AF) in the year 2050 ranges from 5.6 million to
as high as 15.9 million individuals.
Jared W. Magnani et al. Circulation. 2011;124:1982-1993
Atrial Fibrillation
An Epidemic
www.theafibclinic.com
3. 0
5
10
15
20
25
30
35
50-59 60-69 70-79 80-89
3000838-7
%
Percent of Total Strokes
Attributable to Atrial Fibrillation
Stroke 22(18), 1991
• 500,000 strokes/year in U.S.
• Up to 20% of ischemic strokes occur in
patients with atrial fibrillation
www.theafibclinic.com
4. AF increases Risk and Stroke Severity
• 1061 patients admitted with acute
ischemic stroke
– 20.2% had AF
• Bedridden state
– With AF 41.2%
– Without AF 23.7%
• Odds ratio for bedridden state following stroke due to AF
2.23 (95% CI, 1.87-2.59; P<.0005)
P<.0005
Dulli et al. Neuroepidemiology. 2003;22:118-123.
Atrial Fibrillation
Stroke Risk
www.theafibclinic.com
5. Atrial Fibrillation
Stroke Pathology
3000838-9
Blackshear: Ann Thoracic Surg 61, 1996
Johnson: Eur J Cardiothoracic Surg 17, 2000
Fagan: Echocardiography 17, 2000
• Insufficient contraction of LA and LAA leads to
stagnant blood flow
• Most likely culprit:
• Embolization of LAA clot
• 90% of thrombus found in LAA
• TEE-based risk factors
• Enlarged LAA
• Reduced inflow and outflow velocities
• Spontaneous Echo contrast
www.theafibclinic.com
6. • >90% of strokes in AF
patients are secondary
to LAA emboli
www.theafibclinic.com
16. • Aspirin:
– No data for low risk patients
– Dual therapy can significantly increase risks of bleeding
– If revascularization/CAD indication
• Consider BMS
• Dual therapy: clopidogrel, no aspirin
Atrial Fibrillation and Stroke Prevention
Medical Therapy - Aspirin
www.theafibclinic.com
17. Atrial Fibrillation and Stroke Prevention
Warfarin
3000838-10
Cooper: Arch Int Med 166, 2006
Lip: Thromb Res 118, 2006
• Warfarin still widely used
• Assuming 51 ischemic strokes/1000 pt-yr
• Warfarin prevented 28 strokes at expense of 11
fatal bleeds
• Aspirin prevented 16 strokes at expense
of 6 fatal bleeds
• Time in therapeutic window is low even in clinical
trials
• Discontinuation
• Complications
www.theafibclinic.com
18. • NOACs
– Dabigatran
– Apixaban
– Rivaroxaban
– Edoxaban
• Guidelines
– Novel anticoagulants were added to warfarin as preferred
therapy.
– First line therapy
– Preferred therapy for patients with labile INR
Atrial Fibrillation and Stroke Prevention
NOACs
www.theafibclinic.com
20. Possible drug-drug interactions
Dabigatran Apixaban Edoxaban Rivaroxaban
Atorvastatin P-gp/ CYP3A4 +18% no data yet no effect no effect
Digoxin P-gp no effect no data yet no effect no effect
Verapamil P-gp/ wk CYP3A4
+12–180%
no data yet
+ 53% (slow release)
minor effect
Diltiazem P-gp/ wk CYP3A4 no effect +40% No data minor effect
Quinidine P-gp +50% no data yet +80% +50%
Amiodarone P-gp +12–60% no data yet no effect minor effect
Dronedarone P-gp/CYP3A4 +70–100% no data yet +85% no data yet
Ketoconazole;
itraconazole;
voriconazole;
posaconazole;
P-gp and BCRP/
CYP3A4
+140–150% +100% no data yet up to +160%
19
www.escardio.org/EHRA
Red – contraindicated; orange – reduce dose; yellow – consider dose reduction if another yellow factor present;
hatching – no data available; recommendation made from pharmacokinetic considerations
www.theafibclinic.com
21. Interaction Dabigatran Apixaban Edoxaban Rivaroxaban
Fluconazole CYP3A4 no data no data no data +42%
Cyclosporin;
tacrolimus
P-gp no data no data no data +50%
Clarithromycin;
erythromycin
P-gp/ CYP3A4 +15–20% no data no data +30–54%
HIV protease
inhibitors
P-gp and BCRP/
CYP3A4
no data strong increase no data up to +153%
Rifampicin;
St John’s wort;
carbamezepine;
phenytoin;
phenobarbital
P-gp and BCRP/
CYP3A4/CYP2J2
-66% -54% -35% up to -50%
Antacids GI absorption -12-30% no data no effect no effect
20
www.escardio.org/EHRA
Red – contraindicated; orange – reduce dose; yellow – consider dose reduction if another yellow factor present;
hatching – no data available; recommendation made from pharmacokinetic considerations
Possible drug-drug interactions
www.theafibclinic.com
22. NOACs in renal dysfunction
Dosing in chronic kidney disease
Dabigatran Apixaban Edoxaban * Rivaroxaban
Note: 75 mg BID approved in US
only **
-if CrCl 15-30 ml/min
- if CrCl 30-49 ml/min
-and other orange factor (e.g.
verapamil)
CrCl 15-29 ml/min: 2.5 mg
BID
Serum creatinine ≥ 1.5 mg/dl
in combination with age ≥80
years or weight ≤60 kg
(SmPC) or with other yellow’
factor: 2.5 mg BID
not available 15 mg OD when CrCl
15-49 ml/min
28
www.escardio.org/EHRA
1. Camm et al, Eur Heart J 2012;33:2719-47
www.theafibclinic.com
23.
24. Study NOAC VKA Outcome
RE-LY Dabigatran
3.3%
Warfarin
3.6%
RR 0.93
95% CI 0.81-1.07
P = 0.31
ARISTOTLE Apixaban
2.1%
Warfarin
3.1%
HR 0.69
95% CI 0.60-0.8
P = < 0.001
ROCKET-AF Rivaroxaban
5.6%
Warfarin
5.4%
HR 1.04
95% CI 0.90-1.20
P = 0.58
Atrial Fibrillation and Stroke Prevention
Large NOAC Trials – Major Bleeding
www.theafibclinic.com
25. Study NOAC VKA Outcome
RE-LY Dabigatran
0.3%
Warfarin
0.7%
RR 0.40
95% CI 0.27-0.60
P= <0.001
ARISTOTLE Apixaban
0.3%
Warfarin
0.8%
HR 0.42
95% CI 0.30-0.58
P = <0.001
ROCKET-AF Rivaroxaban
0.5%
Warfarin
0.7%
HR 0.67
95% CI 0.47-0.93
P = 0.02
Atrial Fibrillation and Stroke Prevention
Large NOAC Trials – Intracranial Hemorrhage
www.theafibclinic.com
26. • Easier to use
• Predictable effect without need for monitoring
– more predictable half-life/elimination surgery
• Fewer food and drug interactions
• Caution when CKD
• Improved efficacy/safety ratio
– But bleeding risk also exists
– WARFARIN BLEEDING IS UNDER/NOT REPORTED
• Reversal Agents
– Available for pradaxa
Atrial Fibrillation and Stroke Prevention
Large NOAC Trials – Intracranial Hemorrhage
www.theafibclinic.com
28. Patient’s choice
Atrial Fibrillation and Stroke Prevention
Challenges with OAC
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1 2 3 4 5 6
CHADS2 Score
p < 0.001
(n=27,164)
AFPatientsUsing
Anticoagulation
Anticoagulation Use Declines
with Increased Stroke Risk1
www.theafibclinic.com
29. Less than 50% of patients eligible are being
treated with OACs
Risk of bleeding
GI bleeding
Hemorrhagic Strokes
Contraindications for anticoagulants:
Bleeding
Hemorrhagic Stroke
Frequent Falls
low Platelet Count
Recent Surgery
Patient’s choice
Atrial Fibrillation and Stroke Prevention
Challenges with OAC
www.theafibclinic.com
30. High Risk (>4%/year) >4
Moderate Risk (2-4%/year) 2-3
Low Risk (<2%/year) 0-1
Atrial Fibrillation and Stroke Prevention
HAS-BLED
www.theafibclinic.com
34. Atrial Fibrillation and Stroke Prevention
LAA Closure – Watchman Device
Canine Model – 30 Day
Canine Model – 45 Day
Human Pathology - 9 Months Post-implant
(Non-device related death)
www.theafibclinic.com
37. Atrial Fibrillation and Stroke Prevention
Watchman – Implant Success
p = 0.04
Study 45-day 12-month
PROTECT AF 87% >93%
CAP 96% >96%
PREVAIL 92% >99%
Implant success defined as deployment and release of the device into the left atrial appendage
Warfarin Cessation PREVAIL Implant
Success
No difference between new
and experienced operators
Experienced Operators
• n=26
• 96%
New Operators
• n=24
• 93% p = 0.28
PROTECT AF and CAP: Reddy, VY et al. Circulation. 2011;123:417-424.
PREVAIL: Holmes, DR et al. JACC 2014; 64(1):1-12.
www.theafibclinic.com
38. Atrial Fibrillation and Stroke Prevention
Watchman – Complications
9.9%
4.8%
4.1% 4.1% 3.8%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
CAP PREVAIL CAP2
Patients
with
Safety
Event
(%)
PROTECT AF
1st Half 2nd Half
n=232 n=231 n=566 n=269 n=579
All Device and/or procedure-related serious adverse events within 7 Days
Learning
Curve
~50% New Operators
in PREVAIL
Source: FDA Oct 2014 Panel Sponsor Presentation.
39. Atrial Fibrillation and Stroke Prevention
Protect AF trial – Bleeding Risk
50
60
70
80
90
100
0 7
Time (months)
Free of
Major
Bleeding
Event
(%)
6 6046 1808 45
Time (days)
Warfarin
+Aspirin
Warfarin
+Aspirin
Aspirin+
Clopidogrel
Aspirin
WATCHMAN
Warfarin
Definition of bleeding: Serious bleeding event that required intervention or hospitalization according to adjudication committee
71%
Relative Reduction
In Major Bleeding
after cessation of
anti-thrombotics
HR = 0.29
p<0.001
WATCHMAN
Device Arm Drug
Protocol
Price, MJ. Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-Term Oral Anticoagulation : Pooled Analysis of the PROTECT-AF
and PREVAIL RCTs. TCT 2014 (abstract)
www.theafibclinic.com
40. Atrial Fibrillation and Stroke Prevention
Watchman Trials Meta Analysis
HR p-value
Efficacy 0.79 0.22
All stroke or SE 1.02 0.94
Ischemic stroke or SE 1.95 0.05
Hemorrhagic stroke 0.22 0.004
Ischemic stroke or SE >7 days 1.56 0.21
CV/unexplained death 0.48 0.006
All-cause death 0.73 0.07
Major bleed, all 1.00 0.98
Major bleeding, non procedure-related 0.51 0.002
0.01 0.1 1 10
Favors WATCHMAN Favors warfarin
Hazard Ratio (95% CI)
Holmes, DR et al. JACC 2014www.theafibclinic.com
41. Atrial Fibrillation and Stroke Prevention
Watchman Trials Meta Analysis
Subgroup Analysis
Subgroup p-value
Age
< 75
0.910
> 75
Sex
Female
0.679
Male
CHADS2
Score
≤ 3
0.758
>3
CHA2DS2-
VASc Score
≤ 4
0.271
>4
HAS-BLED
≤ 2
0.098
>2
History of TIA
Stroke
No
0.623
Yes
0.1 1.0 10.0
Hazard Ratio
Favors WATCHMAN Favors warfarin
Holmes, DR et al. JACC 2014www.theafibclinic.com
42. Atrial Fibrillation and Stroke Prevention
Watchman Trials Meta Analysis
Summary
• WATCHMAN comparable to warfarin for primary efficacy
(HR=0.79)
– Results maintained when all 4 studies were analyzed
– Results consistent across subgroups
• Significant reductions in
– CV mortality
– Hemorrhagic strokes
– Major bleeding post procedure
• Safe alternative to long term OAC
• Significant improvement in quality of life
www.theafibclinic.com
43. Atrial Fibrillation and Stroke Prevention
Conclusion
• Afib burden continues to increase
– Prevelance
– Stroke risk and severity
• NOACs are preferred over warfarin
– Efficacious
– More convenient for patients
– Bleeding still a risk for all oral anticoagulants
• Left atrial appendage closure
– Safe alternative
– Specially advantageous for patients with high bleeding risk
www.theafibclinic.com
Editor's Notes
In order to assess if the severity of AF-associated acute ischemic stroke is worse than ischemic stroke associated with other etiologies, Dulli et al examined an acute ischemic stroke patient population for the clinical characteristics of acute ischemic stroke in patients with and without underlying AF in a retrospective study.
AF was present in 20.2% of the patient population (acute ischemic stroke patients admitted between 1990 and 2001). Many of the factors associated with ischemic stroke varied between patients with AF and without AF. Hypertension, ischemic heart disease (IHD), and other cardioembolic risks were significantly higher in patients with AF. The study also showed that the frequency of the bedridden state was markedly higher in patients with AF (41.2%) versus patients without AF (23.7%); P<.0005. The odds ratio for the bedridden state following stroke with AF was 2.23 (95% confidence interval [CI], 1.87-2.59; P<.0005). The significance of AF in the severity of stroke compared with other variables demonstrated that AF was a strong independent predictor of severe ischemic stroke. The study also showed that the disability caused by acute ischemic stroke increases with age, and is significantly worse when associated with AF in groups aged 65 to 74 (P<.05) and 75 to 84 years (P<.0005).
The study investigators concluded that acute ischemic stroke in the presence of underlying AF is often more severe than ischemic stroke due to other etiologies.